
The company wants to transition to combination therapy of bamlanivimab and etesevimab together for COVID-19 treatment.

The company wants to transition to combination therapy of bamlanivimab and etesevimab together for COVID-19 treatment.

While RT-PCR testing is difficult for confirming a reinfection with the virus, whole genome sequencing may be a more reliable measure.

The ATLAS 2M study results showed non-inferiority in 2-month dosing compared to 1-month dosing for the cabotegravir and rilpivirine long-acting injectable.

The ongoing pandemic has caused a severe decrease in childhood vaccinations, while some rates have recovered, others have not and clinicians are urging caregivers to have their children receive their shots.

Study hoping to show reduced need for respiratory support with the approach failed to do so, though it does appear to limit the need for intubation.

Study finds a 10% reinfection rate amongst a mostly 18-20 year old United States Marine population in a closed setting.


The 2 shot mRNA vaccine has a high efficacy against COVID-19, but long term data for its protection is not there yet, and emerging variants may present a challenge.

Antimicrobials were commonly prescribed during the first wave of the pandemic, and clinicians were successfully guided by antimicrobial stewardship programs.

Increased facility-level vaccine coverage amongst residents and staff was associated with lower cases in the latter population.

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) met today to discuss the blood clots’ issue and offered guidance on heparin usage in these cases.

More than half of urine cultures were found to be contaminated and 1 in 5 of the patients were prescribed an antibiotic.

The two measures were shown to prevent viral outbreaks if at least 60% of a population followed them.

Social identity plays an important role in how antimicrobial stewards see their roles and influences how they communicated with prescribers.

The US Food and Drug Administration released an investigation report on the fall 2020 outbreak of Shiga toxin-producing Escherichia coli (STEC) O157:H7 linked to leafy greens grown in California and updated the Leafy Greens Action Plan.


Carlos del Rio, MD, discusses the United States' pandemic situation in assessing the blood clot events observed in 6 Johnson & Johnson vaccine recipients.

Jason Gallagher, PharmD, adds context behind the FDA and CDC's decision to pause and review blood clotting events in 6 women given the company's COVID-19 vaccine.

The monoclonal antibody cocktail reduced symptomatic infections by 72% in the first week and 93% in following weeks.

In a press conference this morning, leadership of the FDA and CDC discussed why they made the decision on this vaccine and announced an ACIP meeting will be held tomorrow to review the data from the adverse events.

The federal agencies will advise states withhold administration of the Johnson & Johnson one-shot product while investigating risk of a rare blood clot disorder.

Our editor-in-chief writes on the role caregivers play in informing the public on the perks of a more vaccinated population.

New cohort analyses show the popular UK variant is linked to a higher viral load, though patients have not experienced worse likelihood of outcomes.

Infectious diseases are emerging at an alarmingly rapid pace, faster than any other time in human history.

Updated review and meta-analysis identifies the classes of antibiotics most strongly linked to healthcare facility-associated Clostridioides difficile infection.

Despite a growing number of cases, millions gather in India for Hindu festival.

With millions of people vaccinated for COVID-19, A new study, collecting data from CDC's v-safe program, discusses reactions following mRNA-based vaccines.

A recent study looked at the racial disparities amongst people living with HIV and COVID-19 positivity rates.

A retrospective comparative effectiveness study looked at time to clinical improvement or time to death among hospitalized patients who were treated with or without remdesivir.